Skip to main content
Erschienen in: Clinical Research in Cardiology 4/2010

01.04.2010 | Original Paper

Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease

verfasst von: Boris Bigalke, Konstantinos Stellos, Tobias Geisler, Stephan Lindemann, Andreas E. May, Meinrad Gawaz

Erschienen in: Clinical Research in Cardiology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Platelets play a critical role in arterial thrombosis, acute coronary syndrome (ACS) and stroke. Platelet collagen receptor glycoprotein VI (GPVI) is associated with acute coronary events and a poor clinical outcome.

Methods

Between January 2006 and March 2009, we evaluated 2,213 consecutive patients in a prospective study design, who presented with chest pain. Among 1,819 patients (82.2%) who underwent coronary angiography, 1,652 patients (90.8%) showed a coronary and 167 patients (9.2%) a non-coronary origin of chest pain. 901 patients (54.5%) presented with an ACS, 751 (45.5%) with a stable angina pectoris. Clinical outcome was performed by a predefined structured telephone interview after a 3-month follow-up (92.8%:1,533 of 1,652 patients).

Results

Kaplan–Meier analysis for cumulative event-free survival revealed that patients with a elevated baseline GPVI expression had a poorer clinical outcome for cardiovascular death than patients with decreased GPVI levels (log rank; P = 0.040). These results were paralleled in composite cumulative survival that included myocardial infarction, stroke, and cardiovascular death (log rank; P = 0.002). Relative risk of cardiovascular death was found at 1.41 (95% CI 1.08–1.85) for platelet GPVI, 1.64 (95% CI 1.31–2.05) for brain natriuretic peptide, 1.16 (95% CI 0.81–1.64) for troponin-I and 1.33 (95% CI 0.97–1.82) for C-reactive protein.

Conclusions

Patients with CAD presenting increased levels of platelet GPVI had a poorer outcome and may profit from a dual antiplatelet therapy. Thus, GPVI may be a useful prognostic tool for adverse cardiovascular events. Future studies should substantiate GPVI for its potential role of risk prediction and consider its prognostic value to improve risk stratification.
Literatur
1.
Zurück zum Zitat Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK (2009) Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 20:143–149CrossRefPubMed Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK (2009) Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 20:143–149CrossRefPubMed
2.
Zurück zum Zitat Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 16:e148–e304 Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 16:e148–e304
3.
Zurück zum Zitat Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717CrossRefPubMed Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717CrossRefPubMed
4.
Zurück zum Zitat Bigalke B, Geisler T, Stellos K, Langer H, Daub K, Kremmer E, Seizer P, May AE, Lindemann S, Gawaz M (2008) Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J 156:193–200CrossRefPubMed Bigalke B, Geisler T, Stellos K, Langer H, Daub K, Kremmer E, Seizer P, May AE, Lindemann S, Gawaz M (2008) Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J 156:193–200CrossRefPubMed
5.
Zurück zum Zitat Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H, Schonberger T, Kremmer E, Siegel-Axel D, May AE, Gawaz M (2006) Expression of platelet collagen receptor VI is associated with acute coronary syndrome. Eur Heart J 27:2165–2169CrossRefPubMed Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H, Schonberger T, Kremmer E, Siegel-Axel D, May AE, Gawaz M (2006) Expression of platelet collagen receptor VI is associated with acute coronary syndrome. Eur Heart J 27:2165–2169CrossRefPubMed
6.
Zurück zum Zitat Bigalke B, Stellos K, Geisler T, Kremmer E, Seizer P, May A, Lindemann S, Melms A, Luft A, Gawaz M (2009) Expression of platelet glycoprotein vi is associated with transient ischemic attack and stroke. Eur J Neurol [Epub ahead of print] Bigalke B, Stellos K, Geisler T, Kremmer E, Seizer P, May A, Lindemann S, Melms A, Luft A, Gawaz M (2009) Expression of platelet glycoprotein vi is associated with transient ischemic attack and stroke. Eur J Neurol [Epub ahead of print]
7.
Zurück zum Zitat Bigalke B, Stellos K, Stakos D, Joos T, Pötz O, Geisler T, Bischofs C, Kremmer E, Krämer BF, Seizer P, May AE, Lindemann S, Gawaz M (2009) Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome. Thromb Haemost 101:911–915PubMed Bigalke B, Stellos K, Stakos D, Joos T, Pötz O, Geisler T, Bischofs C, Kremmer E, Krämer BF, Seizer P, May AE, Lindemann S, Gawaz M (2009) Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome. Thromb Haemost 101:911–915PubMed
8.
Zurück zum Zitat Bigalke B, Stellos K, Weig HJ, Geisler T, Seizer P, Kremmer E, Pötz O, Joos T, May AE, Lindemann S, Gawaz M (2009) Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol 104:352–357CrossRefPubMed Bigalke B, Stellos K, Weig HJ, Geisler T, Seizer P, Kremmer E, Pötz O, Joos T, May AE, Lindemann S, Gawaz M (2009) Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol 104:352–357CrossRefPubMed
9.
Zurück zum Zitat Brügger-Andersen T, Aarsetøy H, Grundt H, Staines H, Nilsen DW (2008) The long-term prognostic value of multiple biomarkers following a myocardial infarction. Thromb Res 123:60–66CrossRefPubMed Brügger-Andersen T, Aarsetøy H, Grundt H, Staines H, Nilsen DW (2008) The long-term prognostic value of multiple biomarkers following a myocardial infarction. Thromb Res 123:60–66CrossRefPubMed
10.
Zurück zum Zitat Chung I, Choudhury A, Patel J, Lip GY (2009) Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 41:45–51CrossRefPubMed Chung I, Choudhury A, Patel J, Lip GY (2009) Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 41:45–51CrossRefPubMed
11.
Zurück zum Zitat Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R, Bertel O, Frielingsdorf J (2008) Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 97:298–305CrossRefPubMed Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R, Bertel O, Frielingsdorf J (2008) Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 97:298–305CrossRefPubMed
12.
Zurück zum Zitat Geisler T, Kapp M, Göhring-Frischholz K, Daub K, Dösch C, Bigalke B, Langer H, Herdeg C, Gawaz M (2008) Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 94:743–747CrossRefPubMed Geisler T, Kapp M, Göhring-Frischholz K, Daub K, Dösch C, Bigalke B, Langer H, Herdeg C, Gawaz M (2008) Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 94:743–747CrossRefPubMed
13.
Zurück zum Zitat Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT (2008) Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 199:3–11CrossRefPubMed Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT (2008) Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 199:3–11CrossRefPubMed
14.
Zurück zum Zitat James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 108:275–281CrossRefPubMed James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 108:275–281CrossRefPubMed
15.
Zurück zum Zitat Kisucka J, Chauhan AK, Zhao BQ, Patten IS, Yesilaltay A, Krieger M, Wagner DD (2009) Elevated levels of soluble P-selectin in mice alter blood–brain barrier function, exacerbate stroke and promote atherosclerosis. Blood 113:6015–6022CrossRefPubMed Kisucka J, Chauhan AK, Zhao BQ, Patten IS, Yesilaltay A, Krieger M, Wagner DD (2009) Elevated levels of soluble P-selectin in mice alter blood–brain barrier function, exacerbate stroke and promote atherosclerosis. Blood 113:6015–6022CrossRefPubMed
16.
Zurück zum Zitat Kurz K, Schild C, Isfort P, Katus HA, Giannitsis E (2009) Serial and single time-point measurements of cardiac troponin T for prediction of clinical outcomes in patients with acute ST-segment elevation myocardial infarction. Clin Res Cardiol 98:94–100CrossRefPubMed Kurz K, Schild C, Isfort P, Katus HA, Giannitsis E (2009) Serial and single time-point measurements of cardiac troponin T for prediction of clinical outcomes in patients with acute ST-segment elevation myocardial infarction. Clin Res Cardiol 98:94–100CrossRefPubMed
17.
Zurück zum Zitat Möckel M, Müller R, Vollert JO, Müller C, Danne O, Gareis R, Störk T, Dietz R, Koenig W (2007) Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol 96:604–612CrossRefPubMed Möckel M, Müller R, Vollert JO, Müller C, Danne O, Gareis R, Störk T, Dietz R, Koenig W (2007) Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol 96:604–612CrossRefPubMed
18.
Zurück zum Zitat Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL (2008) Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29:1096–1102CrossRefPubMed Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL (2008) Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29:1096–1102CrossRefPubMed
19.
Zurück zum Zitat Ndrepepa G, Braun S, Mehilli J, Niemöller K, Schömig A, Kastrati A (2007) A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. Clin Res Cardiol 96:30–37CrossRefPubMed Ndrepepa G, Braun S, Mehilli J, Niemöller K, Schömig A, Kastrati A (2007) A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. Clin Res Cardiol 96:30–37CrossRefPubMed
20.
Zurück zum Zitat Patrono C, García Rodríguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373–2383CrossRefPubMed Patrono C, García Rodríguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373–2383CrossRefPubMed
21.
Zurück zum Zitat Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E (2002) Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105:1760–1763CrossRefPubMed Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E (2002) Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105:1760–1763CrossRefPubMed
22.
Zurück zum Zitat Sanchis J, Bosch X, Bodí V, Bellera N, Núñez J, Benito B, Ordóñez J, Consuegra L, Heras M, Llècer A (2008) Combination of clinical risk profile, early exercise testing and circulating biomarkers for evaluation of patients with acute chest pain without ST-segment deviation or troponin elevation. Heart 94:311–315CrossRefPubMed Sanchis J, Bosch X, Bodí V, Bellera N, Núñez J, Benito B, Ordóñez J, Consuegra L, Heras M, Llècer A (2008) Combination of clinical risk profile, early exercise testing and circulating biomarkers for evaluation of patients with acute chest pain without ST-segment deviation or troponin elevation. Heart 94:311–315CrossRefPubMed
23.
Zurück zum Zitat Thomas L, Müller M, Schumann G, Weidemann G, Klein G, Lunau S, Pick KH, Sonntag O (2005) Consensus of DGKL and VDGH for interim reference intervals on enzymes in serum. J Lab Med 29:301–308 Thomas L, Müller M, Schumann G, Weidemann G, Klein G, Lunau S, Pick KH, Sonntag O (2005) Consensus of DGKL and VDGH for interim reference intervals on enzymes in serum. J Lab Med 29:301–308
24.
Zurück zum Zitat Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA (1993) Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 88:37–42PubMed Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA (1993) Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 88:37–42PubMed
25.
Zurück zum Zitat Tousoulis D, Kampoli AM, Stefanadi E, Antoniades C, Siasos G, Papavassiliou AG, Stefanadis C (2008) New biochemical markers in acute coronary syndromes. Curr Med Chem 15:1288–1296CrossRefPubMed Tousoulis D, Kampoli AM, Stefanadi E, Antoniades C, Siasos G, Papavassiliou AG, Stefanadis C (2008) New biochemical markers in acute coronary syndromes. Curr Med Chem 15:1288–1296CrossRefPubMed
26.
Zurück zum Zitat Waxman DA, Hecht S, Schappert J, Husk G (2006) A model for troponin I as a quantitative predictor of in-hospital mortality. J Am Coll Cardiol 48:1755–1762CrossRefPubMed Waxman DA, Hecht S, Schappert J, Husk G (2006) A model for troponin I as a quantitative predictor of in-hospital mortality. J Am Coll Cardiol 48:1755–1762CrossRefPubMed
Metadaten
Titel
Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease
verfasst von
Boris Bigalke
Konstantinos Stellos
Tobias Geisler
Stephan Lindemann
Andreas E. May
Meinrad Gawaz
Publikationsdatum
01.04.2010
Verlag
Springer-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 4/2010
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-009-0109-y

Weitere Artikel der Ausgabe 4/2010

Clinical Research in Cardiology 4/2010 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.